GAINESVILLE, Fla., March 1, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the patent office of Mexico, Instituto Mexicano de la Propiedad Industrial (IMPI), has issued two new patents that broaden the international intellectual property coverage of Quick-Med's MultiStat® technology. MultiStat is a groundbreaking formulation designed to prevent and repair damage caused by exposure to the sun or other burns.
Mexico patent No. 283,269 is entitled "Methods and Compositions for Reducing UV-Induced Inhibition of Collagen Synthesis in Human Skin." It remains in effect until April 2, 2019.
Mexico patent No. 282,908 is entitled "Methods and Compositions for Protecting and Restoring Skin using Selective MMP Inhibitors." It remains in effect until December 18, 2021.
These two new patents are part of a portfolio that Quick-Med has licensed from the University of Michigan and are similar to U.S. Patent No. 6,683,069 entitled "Methods and Compositions for Reducing UV-Induced Inhibition of Collagen Synthesis in Human Skin" and U.S. Patent No. 7,141,238 entitled "Compositions for Reducing UV-Induced Inhibition of Collagen Synthesis in Human Skin."
"These new patents for our MultiStat technology, covering methods and compositions for reducing UV-induced inhibition of collagen, significantly expand and strengthen the international IP estate under our licensing agreement with the University of Michigan," said Dr. Jerry Olderman, Quick-Med's Vice President of Research & Development. "With the ongoing increase of the 'sunbelt' population and a growing interest in outdoor recreation, skin damage caused by sun exposure continues to affect a significant and growing percent of the population. These patents help to ensure greater protection for the methods of using our MultiStat technology to prevent and repair sun-damaged skin and reduce wrinkles in aging skin."
The skin's healing process from sun damage requires the generation of collagen, a critical protein in skin that is also found in hair, bones, arteries and organs, to replace the damaged tissue. The key to natural healing is the replacement of damaged collagen. There are several adjuncts included in the MultiStat patent claims to treat these conditions, including types (A & B) of UV absorbers, an antioxidant, a retinoid and a broad class of compounds that treat skin wrinkles. The main ingredient is the Matrix Metallo Protease Inhibitor (MMPI) that is used in MultiStat.
The latest patents issued cover both the composition of MultiStat and the process used to produce it. While the main component of the composition is a protease inhibitor, a compound that prevents enzymes from destroying collagen, its other elements include one or more of such agents as a UV block, antioxidant and retinoid.
About MultiStat®
MultiStat is Quick-Med's family of patented matrix metalloproteinase inhibitors (MMPIs), which have been shown to be highly effective in reducing skin wrinkling and aging. The MultiStat family consists of 10 patented compounds, patented formulae for developing other compounds, numerous use or method patents and other intellectual property involving the use of MMP inhibition techniques in skin therapy. These MMPIs, which have been proven effective in broad-based applications, including improving the appearance of fine lines and wrinkles associated with natural aging or sun-induced premature aging and damage, are marketed to the cosmetics industry as performance ingredients in commercially available anti-aging creams. Quick-Med currently owns or has exclusive licenses for topical uses of MultiStat compounds for cosmetic and military applications.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS® technology in traditional wound care products in 2009 and is developing applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: .
The Quick-Med Technologies, Inc. logo is available at
© 2011 Quick-Med Technologies, Inc. All rights reserved. MultiStat®, NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at .
CONTACT: Quick-Med Technologies J. Ladd Greeno, CEO (888) 835.2211 Ext 102 lgreeno@quickmedtech.com Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 casey@stonegateinc.com